Activation and proliferation profiles of M.tuberculosis specific dual functional CD4+T cells from smear negative pulmonary TB patients
PLOS One · 2025
DOI: 10.1371/journal.pone.0327243 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ahmed Esmael und 8 weiteren Autor:innen. Beteiligte Einrichtung: Armauer Hansen Research Institute, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Mycobacterium tuberculosis, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: FIC NIH HHS, NIAID NIH HHS, Armauer Hansen Research Institute, Ethiopia.
Abstract (Originalsprache)
Background
Tuberculosis is a major public health challenge in the resource-limited endemic setting of sub-Saharan Africa. The diagnostic challenge becomes worse for smear-negative TB cases. Even if efforts for non-sputum-based TB diagnostic and prognostic biomarkers, there was limited data on blood-based immunological biomarkers among smear-negative PTB patients.Therefore, we assessed the phenotypic profile (HLA-DR, CD-38, Ki-67) of M. tuberculosis specific CD4 + T cells expressing dual IFN-γ and TNF-α cytokines from smear negative PTB patients in Addis Ababa, Ethiopia. Methodology An institutional-based longitudinal cohort study was conducted in Addis Abeba, Ethiopia, on new smear-negative PTB who were adult and HIV-negative in comparison with multiple comparator groups. A total of 149 (confirmed patients with non-TB respiratory disease −33, smear-negative TB-29, smear-positive TB-34, apparently healthy – 53) study participants was enrolled. The expression level of activation (HLA-DR, CD-38) and proliferation (Ki-67) markers from dual IFN-γ and TNF-α cytokines expressing PPD specific CD4 + T cells were assessed after surface and intracellular cytokine staining. To confirm the presence of M. tuberculosis , MGIT/LJ culture, PCR, and smear microscopy were performed.
Result
The overall level of HLA-DR and CD-38 expression in smear-negative and positive pulmonary TB patients were substantially higher than that of confirmed non-TB respiratory illness, apparently healthy QFT positive and negative study participants (p-value = 0.0127, p-value < 0.0001, p-value = 0.0043, p-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
- Department of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, Ethiopia.
- Department of Medicine, Division of Infectious Diseases and Emory Vaccine Center, Emory University School of Medicine, Emory University, Atlanta, GeorgiaUnited States of America.
- Division of Experimental Medicine, University of California San Francisco, San Francisco, California, United States of America.
ORCID-Profile: Ahmed Esmael, Sebsib Neway
Förderung
- FIC NIH HHS
- NIAID NIH HHS
- Armauer Hansen Research Institute, Ethiopia
- NIH/Fogarty International Center Global Infectious Diseases
- BEI Resources, NIAID, NIH
Zitieren
APA
Esmael, A., Mihret, A., Abebe, T., Mussa, D., Neway, S., Ernst, J., Rengarajan, J., Wassie, L., & Howe, R. (2025). Activation and proliferation profiles of M.tuberculosis specific dual functional CD4+T cells from smear negative pulmonary TB patients. PLOS One. https://doi.org/10.1371/journal.pone.0327243
Vancouver
Esmael A, Mihret A, Abebe T, Mussa D, Neway S, Ernst J, et al. Activation and proliferation profiles of M.tuberculosis specific dual functional CD4+T cells from smear negative pulmonary TB patients. PLOS One. 2025. doi:10.1371/journal.pone.0327243
BibTeX
@article{Esmael2025,
author = {Esmael, Ahmed and Mihret, Adane and Abebe, Tamrat and Mussa, Daniel and Neway, Sebsib and Ernst, Joel and Rengarajan, Jyothi and Wassie, Liya and Howe, Rawleigh},
title = {Activation and proliferation profiles of M.tuberculosis specific dual functional CD4+T cells from smear negative pulmonary TB patients},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0327243}
}
EUVIMED